Iressa

Iressa

gefitinib

Manufacturer:

AstraZeneca

Distributor:

DKSH
Concise Prescribing Info
Contents
Gefitinib
Indications/Uses
1st-line treatment of patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR TK. Treatment of patients w/ locally advanced or metastatic NSCLC who have received previous chemotherapy.
Dosage/Direction for Use
Administration
May be taken with or without food: Tab may be dispersed in ½ glass of non-carbonated drinking water. No other liqd should be used. Drop the tab in water & w/o crushing it, stir until dispersed (approx 10 min). Drink the liqd immediately. Rinse the glass w/ another ½ glass of water & drink. The liqd may also be admin via a nasogastric tube.
Special Precautions
Interstitial lung disease (ILD). Perform periodic liver function tests. Monitor patients taking warfarin for changes in prothrombin time or INR. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescents.
Adverse Reactions
Diarrhea, nausea, vomiting, stomatitis; elevations in ALT, AST, total bilirubin, blood creatinine; anorexia, skin reactions (eg, rash, acne, dry skin, pruritus), asthenia, epistaxis, haematuria, proteinuria, nail & eye disorders, alopecia, pyrexia, dehydration, dry mouth, ILD.
Drug Interactions
Reduced efficacy w/ phenytoin, carbamazepine, rifampicin, barbiturates & St. John's wort. Increased mean AUC w/ itraconazole. Reduced mean AUC w/ ranitidine. Increased INR &/or bleeding events w/ warfarin.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EB01 - gefitinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Iressa FC tab 250 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in